RESULTS	Visual acuity ( VA ) outcomes seen at month 24 in ranibizumab groups were consistent through month 36 ; the proportions of patients who gained 15 letters from baseline at month 36 in the sham/0 .5 mg , 0.3 mg , and 0.5 mg ranibizumab groups were 19.2 % , 36.8 % , and 40.2 % , respectively , in RIDE and 22.0 % , 51.2 % , and 41.6 % , respectively , in RISE .\